Testing for Occult Cancer in Patients with Idiopathic Deep Vein Thrombosis – A Decision Analysis

Summary

Objective. To determine the effectiveness and cost-effectiveness of testing for occult cancer in idiopathic deep vein thrombosis (IDVT). Design. Threshold analysis was performed on the risk-adjusted cancer prevalence in a cost-effectiveness model of ideal testing for selecting cancers with potentially desirable utility (candidate cancers). Decision analysis was employed to compare different testing programs for candidate cancers with that of no testing. Life expectancy (LE) of early- and late-detected cancers and costs of testing were the dimensions of utility. Cost-effectiveness was expressed as marginal cost per year of life saved. The perspective of the third payer was adopted, and a discount rate of 3% was applied to both costs and benefits. Data sources. Risk of cancer in IDVT, testing policies, test characteristics, and LE were gathered from literature. Costs were provided from our hospital rate book and accounting service. Results. Ideal testing would support a gain of LE of 40 days or more for prostate, colon and bladder cancer in males and for colon, breast and endometrium cancer in females aged from 60 to 69 years. Testing females with colonoscopy and mammography in any sequence provides 70 days of life gained. Testing males with colonoscopy provides 27 days of life gained. Lower and older ages reduce testing effectiveness. The qualitative results are stable over plausible ranges of test characteristics, while variations in the value of benefit for early cancer diagnosis may modify the strategy. Incremental cost-effectiveness ranges from $ 1,789 to $ 6,979 per year of life gained. Conclusions. According to the effectiveness criterion adopted, the only worthwhile investigation strategy includes colon and breast cancer in females. Testing for colon cancer in males is desirable at a lower criterion of effectiveness. All the strategies are cost effective.

• References

• 1 Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 1982; 96: 556-560
• 2 Aderka D, Brown A, Zelikowski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 1986; 57: 1846-1849
• 3 Goldberg RJ, Seneff M, Gore JM. et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987; 147: 251-253
• 4 Griffin MR, Stanton AW, Brown ML. et al. Deep venous thrombosis and ' pulmonary embolism, risk of subsequent malignant neoplasm. Arch Intern Med 1987; 147: 1907-1911
• 5 Monreal M, Salvador R, Soriano V, Sabria M. Cancer and deep venous thrombosis. Arch Intern Med 1988; 148: 485
• 6 Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Ma CallejasJ, Martorelli A. Occult cancer in patients with venous thrombosis. A systematic approach. Cancer 1991; 67: 541-545
• 7 Prandoni P, Lensing AWA, Bueller HR. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133
• 8 Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Ribas MundoM. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest 1993; 103: 816-819
• 9 Nordstrom M, Lindblad B, Anderson H, Bergquist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BM J 1994; 308: 891-894
• 10 Pistorius MA, Le MennerG, Planchon B. Thromboses veineuses profondes et cancer. Evaluation a un an du bilan étiologique des patients hospitalisés en medicine interne. J Mal Vase 1994; 19: 273-277
• 11 Bastounis EA, Karayiannakis AJ, Makri GG, Alexiou D, Papalambros EL. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med 1996; 239: 153-156
• 12 Comuz J, Pearson SD, Creager MA, Cook F, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125: 785-793
• 13 Pearson SD, Lee TH, McCabe-Hassan S, Dorsey JL, Goldhaber SZ. A critical pathway to treat proximal lower-extremity deep vein thrombosis. Am J Med 1966; 100: 283-289
• 14 Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med 1980; 302: 1100-1117
• 15 Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer. Estimates based in the Connecticut Tumor Registry. N Engl J Med 1986; 315: 1394-1397
• 16 Cancer in Italy. Incidence data from Cancer Registries. 1983-1987 Zanetti R, Crosignani P. (eds) Lega Italiana per Ia lotta contro i tumori, Associazi- one Italiana di Epidemiologia. Torino: 1992
• 17 Boring CC, Squires TS, Tong T, Montgomery S. Cancer Statistics, 1994. CA Cancer J Clin 1994; 44: 7-26
• 18 Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy. I. Validation of the methods. Am J Med 1982; 73: 883-888
• 19 Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy. II. Use in medical decision-making. Am J Med 1982; 73: 889-897
• 20 Weinstein MC, Siegel JE, Gold MR, Karmlet MS, Russel LB. for the Panel on Cost-Effectiveness in Health and Medicine Recommendations of the Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258
• 21 Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995; 332: 861-867
• 22 Bowersox J. American Cancer Society adopts new cancer screening guidelines. J Natl Cancer Inst 1992; 84: 1857
• 23 Ellwein LB, Farrow GM. Urinary cytology screening: the decision facing the asymptomatic patient. Med Dec Making 1988; 08: 110-119
• 24 Patnick J, Austoker J, Wolff T. Revision of “NHS breast screening: the facts”: an evaluation. J Med Screening 1995; 02: 15-17
• 25 Pace S, Grassi A, Ferrero S, Figliolini N, Catania R, Labi FL, Pachi A, Fig lioliniM. Diagnostic methods of early detection of endometrial hyperplasia and cancer. Eur J Gynaec Oncol 1995; 26: 373-381
• 26 Shimbo F, Glick HA, Eisenberg JM. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Ass Health Care 1994; 10: 359-375
• 27 Robinson MHE, Moss SM, Hardcatsle JD, Whynes DK, Chamberlain JO, Mangham CM. Effect of retesting with dietary restriction in haemoccult screening for colorectal cancer. J Med Screening 1995; 2: 41-44
• 28 Allison JE, Tekawa IS, Ransom U, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-159
• 29 Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med 1993; 153: 2529-2537
• 30 Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-294
• 31 Mettlin C, Lee F, Drago J. Murphy GP and the Investigators of the American Cancer Society National Prostate Cancer Detection Project. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949-2958
• 32 Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994; 272: 773-780
• 33 Gourlay W, Chan V, Gilks CB. Screening for urothelial malignancies by cytologic analysis and flow cytometry in a community urologic practice: a prospective study. Mod Pathol 1995; 08: 394-397
• 34 Farrow GM. Pathologist’s role in bladder cancer. Semin Oncol 1979; 06: 198-215
• 35 Geller AC, Brooks DR, Barber CE, Koh HK, Lew RA, Wax S, Prout MN. Advances in screening protocols for the detection of early bladder cancer. JOccupMed 1990; 32: 929-935
• 36 Chen H-H, Tabar L, Fagerberg G, Duffy SW. Effect of breast cancer screening after age 65. J Med Screening 1995; 2: 14-16
• 37 UK trial of early detection of breast cancer group. Specificity of screening in United Kingdom trial of early detection of breast cancer. Br Med J 1992; 304: 246-349
• 38 Shipley CF, 3rd Simmons CL, Nelson GH. Comparison of transvaginal sonography with endometrial biopsy in asymptomatic postmenopausal women. J Ultrasound Med 1994; 13: 99-104
• 39 Osmers R, Volksen M, Rath W, Kuhn W. Vaginosonography detection of endometrial cancer in postmenopausal women. Int J Gynecol Obstet 1990; 32: 35-37
• 40 Tsuda H, Kawabata M, Kawabata K, Yamamoto K, Hidaka A, Umesaki N. Comparison between transabdominal and transvaginal ultrasonography for identifying endometrial malignancies. Gynecol Obstet Invest 1995; 40: 271-273
• 41 Mandel JS, Bond JH, Church TR. et al, for the Minnesota Colon Cancer Control Study Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-1371
• 42 Mettlin C, Murphy GP, Lee F. et al, for the Investigators of the American Cancer Society-National Prostate Cancer Detection Project Characteristics of prostate cancers detected in a multimodality early detection program. Cancer 1993; 72: 1701-1708
• 43 Messing EM, Young TB, Hunt VB. et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995; 45: 387-397
• 44 Duffy SW, Tabar L, Fegerberg G. et al. Breast screening, prognostic factors and survival - results from Swedish two-county study. Br J Cancer 1991; 64: 1133-1138
• 45 Chen H-H, Tabar L, Fagerberg G, Duffy SW. Effect of breast cancer screening after age 65. J Med Screening 1995; 02: 10-14
• 46 Tabemero JM, Alonso MC, Ojeda B. et al. Endometrial cancer stages I and Analysis of survival and prognostic factors. Eur J Gynec Oncol 1995; 16: 18-25
• 47 Feinlab M, Zelen M. Some pitfalls in the evaluation of screening programs. Arch Environ Health 1969; 19: 412-415
• 48 Koss LG, Melamed MR, Kelly RE. Further cytologic and histologic studies of bladder lesions in workers exposed to para-aminodiphenyl: progress report. JNCI 1969; 43: 233-243
• 49 Shapiro S, Goldberg JD, Hutchinson GB. Lead-time in breast cancer screening detection and implications for periodicity of screening. Am J Epidemiol 1974; 100: 357-366
• 50 Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983; 118: 865-886
• 51 Moskowitz M. Breast cancer, age-specific growth rates and screening strategies. Radiology 1986; 161: 37-41
• 52 Tabar L, Faberg G, Day NE, Holmberg L. “What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 1987; 55: 547-551
• 53 Duffy SW, Chen HH, Tabar L, Day NE. Estimation of main sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med 1995; 14: 1531-1543
• 54 Eddy DM. Screening for cervical cancer. Ann Intern Med 1990; 113: 214-226
• 55 Shapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening: a decision analysis model. Ann Intern Med 1993; 118: 838-843
• 56 Eddy DM. Screening for breast cancer. Ann Intern Med 1989; 111: 389-399
• 57 O’Meara III JJ, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330: 1864-1869
• 58 Littenberg B. A practice guideline revisited: screening for hypertension. Ann Intern Med 1995; 122: 937-939
• 59 Tabar L, Fagerberg CJG, Gad A. et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985; 01: 829-832
• 60 Weller D, Moss J, Hiller J, Thomas D, Edwards J. Screening for colorectal cancer: what are the costs?. Int J Technol Ass Health Care 1995; 11: 26-39
• 61 Plans P, Casademont L, Salleras L. Cost-effectivensss of breast cancer screening in Spain. Inti J Tech Ass Health Care 1996; 12: 146-150